- Home
- Companies
- Myeloid Therapeutics
- Products
- Myeloid - Model MT-302 (TROP2-FcA LNP) ...
Myeloid - Model MT-302 (TROP2-FcA LNP) - In Vivo Programming Pipeline
Emerging from the Company’s proprietary ATAK™ CAR receptor library, Myeloid’s novel in vivo engineering platform specifically targets and activates myeloid cells to elicit broader anti-tumor adaptive immunity. Through this approach, Myeloid demonstrates that delivery of lipid-nanoparticles (LNPs) encapsulating mRNA results in uptake and selective expression by myeloid cells in vivo, leading to potent tumor killing in multiple cold tumor models.
The Company’s lead in vivo program, MT-302, is a TROP2-targeting in vivo CAR designed for expression within the myeloid compartment. TROP2 is a tumor associated antigen expressed widely on epithelial tumors, including some of the most difficult to treat cancers. Treatment with MT-302 has demonstrated monotherapy activity in a TROP2/TNBC model, confirming the potency of programmed myeloid cells in the absence of T cells. Myeloid believes that MT-302 has significant advantages over TROP2-ADC approaches through its ability to engage the full immune response. Myeloid has initiated a Phase 1 clinical study with MT-302 for patients with TROP2-expressing tumors.